Clinical Trials Sponsored by Hoosier Cancer Research Network

Total 487 results

Ashwin Somasundaram
EMD Serono; University of North Carolina, Chapel Hill

Completed

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

Gastric Adenocarcinoma | Metastasis | Esophageal Adenocarcinoma | HER-2 Gene Amplification

United States
Roberto Pili
Syndax Pharmaceuticals; Clinigen, Inc.; Indiana University Melvin and Bren Simon...

Active, not recruiting

High Dose IL 2 and Entinostat in RCC

Renal Cell Carcinoma

United States
Hoosier Cancer Research Network
University of Sydney; Bionomics Limited; Australia New Zealand Gynaecological...

Withdrawn

BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients

Ovarian Cancer

United States, Australia, New Zealand
Hoosier Cancer Research Network
United States Department of Defense; Indiana University School of Medicine; Walther...

Terminated

A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer

Breast Cancer

United States, Peru
Joshua Zeidner
University of North Carolina, Chapel Hill; Stemline Therapeutics, Inc.

Recruiting

Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents (TAGALONG)

Acute Myeloid Leukemia

United States
Shadia Jalal, MD
Astex Pharmaceuticals, Inc.; Indiana University School of Medicine

Completed

Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer | Extensive-stage Small Cell Lung Cancer

United States
Larry Cripe, MD
Celgene Corporation; Ortho Biotech Clinical Affairs, L.L.C.; Walther Cancer Institute

Terminated

Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Nasser Hanna, M.D.
Bristol-Myers Squibb; Eli Lilly and Company; Walther Cancer Institute

Completed

Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Cancer Research Network
Sanofi

Unknown

Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery

Breast Cancer

United States
Ontario Cancer Research Network

Unknown

PR.7 Companion Trial: Effect of Intermittent Versus Continuous Androgen Suppression on Bone Loss and Body Composition

Prostate Cancer

Canada
Hoosier Cancer Research Network
United States Department of Defense; Emory University; Indiana University School...

Terminated

Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer

Breast Cancer

United States
Bryan Schneider, MD
Hoosier Cancer Research Network; Walther Cancer Institute; Vera Bradley Foundation... and other collaborators

Completed

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

Breast Cancer | Malignant Neoplasm of Breast

United States
Matthew Galsky
Bristol-Myers Squibb; Icahn School of Medicine at Mount Sinai

Completed

Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

Bladder Cancer

United States
Roberto Pili
Bristol-Myers Squibb; Syndax Pharmaceuticals; Indiana University School of Medicine

Active, not recruiting

Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Bryan Schneider, MD
Pfizer; Genentech, Inc.; Indiana University; Foundation Medicine; Vera Bradley Foundation...

Recruiting

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)

Breast Cancer | Triple Negative Breast Cancer

United States
Arkadiusz Z. Dudek, MD
Bristol-Myers Squibb; Eli Lilly and Company; HealthPartners Institute Regions...

Terminated

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Mesothelioma, Malignant

United States
Kyoto Breast Cancer Research Network

Terminated

Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

Breast Cancer

Japan
Cancer Research Network
Genentech, Inc.

Completed

An Observational Study of Current Practice Pattern on the Treatment of Women With Metastatic Breast Cancer Whose Tumors Overexpress Her2neu

Breast Cancer

United States
Kyoto Breast Cancer Research Network

Completed

Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer

Breast Cancer

Japan
University Health Network, Toronto
Ontario Cancer Research Network

Completed

IMRT Lower Limb Soft Tissue Sarcoma

Sarcoma

Canada
Japan Breast Cancer Research Network

Completed

Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer

Breast Neoplasms

Japan
Japan Breast Cancer Research Network

Terminated

Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer

Breast Neoplasms

Japan
Trinitas Comprehensive Cancer Center
Aptium Oncology Research Network

Unknown

Guided Relaxation Training for the Reduction of Self-Reported Stress in Individuals With Newly Diagnosed Breast Cancer (09-IM-01)

Breast Cancer

United States
Aiwu Ruth He, MD
Merck Sharp & Dohme LLC; Georgetown University; The Cleveland Clinic; Hoosier Cancer... and other collaborators

Terminated

Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron

Advanced Cholangiocarcinoma

United States
Kyoto Breast Cancer Research Network
Pfizer

Completed

Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female

Taiwan, Japan, Korea, Republic of, Australia, Hong Kong
Cancer Research Network
Hoffmann-La Roche

Completed

A Study of Weekly Taxotere and Xeloda in Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Hope Rugo, MD
Johns Hopkins University; Pfizer; Gilead Sciences; Hoosier Cancer Research Network and other collaborators

Recruiting

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe)

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Unresectable Breast Carcinoma | Stage IIIC Breast Cancer | Triple-Negative Breast Carcinoma | Stage III Breast Cancer

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma

United States, Puerto Rico
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Prostate Adenocarcinoma | Stage IIIB Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States, Puerto Rico
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumor | Metastatic Malignant Neoplasm in the Liver | Stage I Pancreatic Neuroendocrine Tumor AJCC v8 | Stage II Pancreatic Neuroendocrine Tumor AJCC v8 | Stage III Pancreatic Neuroendocrine Tumor AJCC v8

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial (PROBE)

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Metastatic Melanoma | Metastatic Cutaneous Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal Melanoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Metastatic Small Intestinal Adenocarcinoma | Stage III Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIA Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIB Small Intestinal Adenocarcinoma AJCC v8 | Stage IV Small Intestinal Adenocarcinoma AJCC v8

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Breast Cancer

United States, Puerto Rico, Canada
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Gallbladder Cancer AJCC v8 | Stage IIIA Gallbladder Cancer AJCC v8 | Stage IIIB Gallbladder Cancer AJCC v8 | Unresectable Extrahepatic... and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

Lymphoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditions

United States, Puerto Rico
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer

Bladder Cancer

United States, Canada
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)

Breast Cancer

United States, Puerto Rico
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

S1204, Viral Screening in Newly Diagnosed Cancer Patients

Cancer

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Terminated

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Recurrent Lung Adenocarcinoma | Stage IV Lung Adenocarcinoma | Recurrent Large Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma | Stage IV Large Cell Lung Carcinoma

United States, Mexico
National Cancer Research Network

Unknown

Genetics of Women With Lobular Carcinoma in Situ of the Breast

Breast Cancer

United Kingdom
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Lung Non-Small Cell Carcinoma
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

Malignant Solid Neoplasm

United States

Clinical Trials Sponsored by Hoosier Cancer Research Network

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations